Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Group of systemic vasculitis with a strong association with ANCA. The disorders are characterized by necrotizing inflammation of small and medium size vessels, with little or no immune-complex deposits in vessel walls.
MeSH Number(s)
C14.907.940.897.249
C20.111.193
Concept/Terms
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis
- ANCA-Associated Vasculitis
- ANCA Associated Vasculitis
- Vasculitis, ANCA-Associated
- Pauci-Immune Vasculitis
- Pauci Immune Vasculitis
- Pauci-Immune Vasculitides
- Vasculitides, Pauci-Immune
- Vasculitis, Pauci-Immune
- ANCA-Associated Vasculitides
- ANCA Associated Vasculitides
- ANCA-Associated Vasculitide
- Vasculitide, ANCA-Associated
- Vasculitides, ANCA-Associated
Below are MeSH descriptors whose meaning is more general than "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis".
Below are MeSH descriptors whose meaning is more specific than "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis".
This graph shows the total number of publications written about "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis" by people in Harvard Catalyst Profiles by year, and whether "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2009 | 1 | 0 | 1 |
2010 | 2 | 0 | 2 |
2011 | 5 | 0 | 5 |
2012 | 3 | 3 | 6 |
2013 | 9 | 0 | 9 |
2014 | 6 | 2 | 8 |
2015 | 4 | 2 | 6 |
2016 | 1 | 1 | 2 |
2017 | 5 | 2 | 7 |
2018 | 6 | 1 | 7 |
2019 | 7 | 0 | 7 |
2020 | 12 | 2 | 14 |
2021 | 8 | 2 | 10 |
2022 | 6 | 0 | 6 |
2023 | 17 | 0 | 17 |
2024 | 2 | 0 | 2 |
Below are the most recent publications written about "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis" by people in Profiles.
-
Diagnosis and management of ANCA-associated vasculitis. Lancet. 2024 Feb 17; 403(10427):683-698.
-
Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial. Ann Rheum Dis. 2024 Feb 15; 83(3):351-359.
-
Incidence of Pneumocystis Jiroveci Pneumonia in Patients With ANCA-Associated Vasculitis Initiating Therapy With Rituximab or Cyclophosphamide. Arthritis Care Res (Hoboken). 2024 Feb; 76(2):288-294.
-
The Association Between Age at Diagnosis and Disease Characteristics and Damage in Patients With ANCA-Associated Vasculitis. Arthritis Rheumatol. 2023 12; 75(12):2216-2227.
-
Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study. Rheumatology (Oxford). 2023 08 01; 62(8):2850-2854.
-
Pan American League of Associations for Rheumatology Guidelines for the treatment of ANCA-associated vasculitis. Lancet Rheumatol. 2023 Aug; 5(8):e483-e494.
-
Ocular manifestations of ANCA-associated vasculitis. Rheumatology (Oxford). 2023 07 05; 62(7):2517-2524.
-
Comparative Effectiveness of Rituximab- Versus Cyclophosphamide-Based Remission Induction Strategies in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis for the Risk of Kidney Failure and Mortality. Arthritis Rheumatol. 2023 09; 75(9):1599-1607.
-
Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis. Nephrol Dial Transplant. 2023 Jun 30; 38(7):1655-1665.
-
Steroid sparing in vasculitis: Myth or reality? Best Pract Res Clin Rheumatol. 2023 03; 37(1):101843.